Profound Medical (PROF) Price & Analysis

83 Followers

PROF Stock Chart & Stats

$6.85

$0.41(5.99%)

At close: Jul 24 4:00 PM EDT

$6.85

$0.41(5.99%)

Day’s Range― - ―

52-Week Range$4.80 - $8.95

Previous CloseN/A

Volume272.42K

Average Volume (3M)222.65K

Market Cap

$251.93M

Enterprise Value$298.96M

Total Cash (Recent Filing)$38.21M

Total Debt (Recent Filing)$7.37M

Price to Earnings (P/E)―

Beta0.93

Next Earnings

Nov 05, 2026

EPS Estimate

-0.19

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.97

Shares Outstanding36,532,593

10 Day Avg. Volume440,365

30 Day Avg. Volume222,646

Financial Highlights & Ratios

PEG Ratio-0.20

Price to Book (P/B)3.58

Price to Sales (P/S)14.48

P/FCF Ratio-6.07

Enterprise Value/Market Cap1.19

Enterprise Value/Revenue15.76

Enterprise Value/Gross Profit21.97

Enterprise Value/Ebitda-8.94

Forecast

1Y Price Target

$11.33

Price Target Upside65.45% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)-0.59

Revenue Forecast (FY)$17.76M

Bulls Say, Bears Say

Bulls Say

Strong Revenue Growth And Gross MarginsRapid revenue expansion combined with a healthy gross margin indicates growing commercial adoption and favorable economics for the medical-device platform. If sustained, this combination can provide increasing contribution toward operating costs and support reinvestment as the installed base expands.

Growing Installed Base And Qualified Sales PipelineAn expanding installed base creates a foundation for recurring procedure-related consumables revenue, while the qualified pipeline supports additional capital placements. Together, these assets can broaden customer reach and increase future utilization-based revenue over the next several quarters.

Clinical Differentiation And Imaging PartnershipThe Telix collaboration could strengthen TULSA-PRO's position within prostate-care pathways by linking molecular imaging information with MRI-guided treatment planning. Greater physician education and patient-selection support may improve awareness, adoption, and the platform's clinical differentiation over time.

Bears Say

Deep Ongoing Operating LossesProfound remains far from profitability despite improving year-over-year results, with operating costs still substantially above revenue. Persistent losses can delay self-funded growth, constrain capital allocation, and leave earnings power dependent on achieving significant scale and expense leverage.

Heavy And Worsening Cash BurnNegative operating and free cash flow indicate that commercialization currently consumes substantial cash rather than funding expansion internally. If burn remains elevated, the company may need additional financing, reducing flexibility and increasing execution pressure while it works toward break-even.

Installation And Revenue-conversion DelaysLong implementation timelines delay the transition from equipment shipment to recurring procedure revenue and can make quarterly results uneven. This execution friction may slow installed-base utilization, defer cash generation, and complicate conversion of the qualified pipeline into reported revenue.

Profound Medical News

Profound Medical enters co-education agreement with Telix Pharmaceuticals

Profound Medical (PROF) announced it is entering into a co-education agreement with Telix Pharmaceuticals (TLX). The agreement establishes...

3d ago

TLX

PROF

Profound Medical sees Q3 revenue $9.8M-$10M, consensus $9.56M

Sees Q3 gross margin over 70%. “The significant increase in revenue we expect to report this quarter represents...

5d ago

PROF

Profound Medical, Telix Join Forces to Advance PSMA-Guided Prostate Care

An announcement from Profound Medical ( ($TSE:PRN) ) is now available. Profound Medical has entered into a co-education...

3d ago

PROF

Profound Medical Forecasts Record Q3 Revenue, Far Exceeds Street Estimates

Profound Medical ( ($TSE:PRN) ) has shared an announcement. Profound Medical expects to report record preliminary third-quarter 2026...

5d ago

PROF

Profound Medical initiated with a Buy at Titan Partners

Titan Partners initiated coverage of Profound Medical (PROF) with a Buy rating and $12 price target The company’s...

1M ago

PROF

Profound Medical to Present at BIG10 Growth Conference

Profound Medical ( ($TSE:PRN) ) has issued an update. On September 3, 2026, Profound Medical Corp. announced that...

1M ago

PROF

Profound Medical Names Richard Fabian as New President

Profound Medical ( ($TSE:PRN) ) has issued an announcement. On Sept. 1, 2026, Profound Medical appointed industry veteran...

1M ago

PROF

Profound Medical Taps Industry Veteran Richard Fabian as President in Leadership Realignment

An update from Profound Medical ( ($TSE:PRN) ) is now available. Profound Medical has appointed industry veteran Richard...

1M ago

PROF

Profound Medical Names Industry Veteran Richard Fabian as President in Leadership Realignment

Profound Medical ( ($TSE:PRN) ) just unveiled an update. Profound Medical has appointed veteran healthcare executive Richard Fabian...

1M ago

PROF

Profound Medical Launches Enhanced TULSA-PRO Software Upgrade

Profound Medical ( ($TSE:PRN) ) has issued an announcement. On August 17, 2026, Profound Medical introduced a new...

2M ago

PROF

Profound Medical Names Interim CFO Amid Leadership Transition

Profound Medical ( ($TSE:PRN) ) has issued an update. Profound Medical Corp. announced on August 14, 2026 that...

2M ago

PROF

Profound Medical CFO Rashed Dewan steps down, Matthew Sobczyk interim CFO

Profound Medical (PROF) announced the promotion of Matthew Sobczyk from Corporate Controller to Interim CFO, effective immediately. Sobczyk,...

2M ago

PROF

Profound Medical Earnings Call Highlights Growth Momentum

Profound Medical (($TSE:PRN)) has held its Q2 earnings call. Read on for the main highlights of the call....

2M ago

PROF

Profound Medical Launches Global Prostate Patient Advocacy Community

Profound Medical ( ($TSE:PRN) ) has issued an update. On August 13, 2026, Profound Medical launched Let’s Huddle,...

2M ago

PROF

PROF FAQ

What was Profound Medical’s price range in the past 12 months?

Profound Medical lowest stock price was $4.80 and its highest was $8.95 in the past 12 months.

What is Profound Medical’s market cap?

Profound Medical’s market cap is $251.93M.

When is Profound Medical’s upcoming earnings report date?

Profound Medical’s upcoming earnings report date is Nov 05, 2026 which is in 24 days.

How were Profound Medical’s earnings last quarter?

Profound Medical released its earnings results on Aug 06, 2026. The company reported -$0.26 earnings per share for the quarter, missing the consensus estimate of -$0.242 by -$0.018.

Is Profound Medical overvalued?

According to Wall Street analysts Profound Medical’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Profound Medical pay dividends?

Profound Medical does not currently pay dividends.

What is Profound Medical’s EPS estimate?

Profound Medical’s EPS estimate is -0.19.

How many shares outstanding does Profound Medical have?

Profound Medical has 36,532,593 shares outstanding.

What happened to Profound Medical’s price movement after its last earnings report?

Profound Medical reported an EPS of -$0.26 in its last earnings report, missing expectations of -$0.242. Following the earnings report the stock price went down -6.675%.

Which hedge fund is a major shareholder of Profound Medical?

Currently, no hedge funds are holding shares in PROF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Profound Medical Stock Smart Score

Outperform

Fundamentals

Return on Equity

-62.45%

Trailing 12-Months

Asset Growth

30.60%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Profound Medical

Profound Medical Corp., along with its subsidiaries, operates as a commercial-stage medical technology firm. The company specializes in creating magnetic resonance (MR) guided ablation therapies designed to address prostate conditions, uterine fibroids, and to provide palliative pain management. Its market reach extends to Canada, Germany, the United States, and Finland. The company's primary offering is the TULSA-PRO system, which is engineered to integrate with magnetic resonance imaging (MRI) scanners within hospitals and clinical treatment facilities. Additionally, Profound Medical offers Sonalleve, a versatile therapeutic platform that treats uterine fibroids, delivers palliative pain relief for bone metastases, and provides non-invasive solutions for uterine fibroid treatment. Profound Medical Corp. maintains its corporate headquarters in Mississauga, Canada.

Profound Medical (PROF) Earnings & Revenues

Historic Earnings Reports

PROF Stock 12 Month Forecast

Average Price Target

$11.33

▲(65.45% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","8":"$8","13":"$13","5.5":"$5.5","10.5":"$10.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.333333333333334,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$11.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,5.5,8,10.5,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.85,6.323076923076923,6.796153846153846,7.269230769230769,7.742307692307692,8.215384615384615,8.688461538461539,9.161538461538461,9.634615384615385,10.107692307692307,10.580769230769231,11.053846153846154,11.526923076923076,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.85,6.271794871794872,6.693589743589744,7.115384615384615,7.537179487179487,7.958974358974359,8.38076923076923,8.802564102564101,9.224358974358974,9.646153846153847,10.067948717948719,10.48974358974359,10.911538461538463,{"y":11.333333333333334,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.85,6.169230769230769,6.4884615384615385,6.8076923076923075,7.1269230769230765,7.446153846153846,7.765384615384615,8.084615384615384,8.403846153846153,8.723076923076924,9.042307692307691,9.361538461538462,9.680769230769231,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.94,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.07,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.42,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.87,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.76,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.46,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.53,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.86,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.67,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.75,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.38,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.8,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.85,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >